Physician profile
Aasia Butt
NPI 1053721803
$1,990.81
in general payments reported to CMS, 2019-2025
19 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2021: $14.61 · 2022: $133 · 2023: $497 · 2024: $649 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.36 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Dexcom, INC. | $164.17 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $161.01 | 2019-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.01 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $95.46 | 2022-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $90.80 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.29 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $84.20 | 2022-2024 | |
| Amgen INC. | $71.35 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $69.21 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $68.93 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $56.99 | 2024-2025 | Recorlev |
| Lilly USA, LLC | $53.65 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $44.38 | 2019-2023 | |
| Exact Sciences Corporation | $42.80 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.65 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Mylan Specialty L.P. | $17.25 | 2024 | Yupelri |
| Dynavax Technologies Corporation | $16.21 | 2023 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $14.09 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aasia Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.